K Rajender Reddy

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi request reprint Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C
    K Rajender Reddy
    Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Adv Drug Deliv Rev 54:571-86. 2002
  2. doi request reprint Hepatitis C virus. Preface
    K Rajender Reddy
    Department of Hepatology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Clin Liver Dis 12:xiii-xiv. 2008
  3. pmc Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C
    K Rajender Reddy
    University of Pennsylvania, Philadelphia, PA, USA
    Clin Trials 9:102-12. 2012
  4. doi request reprint Response-guided and -unguided treatment of chronic hepatitis C
    K Rajender Reddy
    Department of Medicine, Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia 19104, USA
    Liver Int 32:64-73. 2012
  5. ncbi request reprint Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment
    K Rajender Reddy
    University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Clin Gastroenterol Hepatol 5:124-9. 2007
  6. doi request reprint Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads
    K Rajender Reddy
    Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Gastroenterology 139:1972-83. 2010
  7. ncbi request reprint Coagulopathy in liver disease
    Wojciech Blonski
    K Rajender Reddy, MD Division of Gastroenterology, Hospital of the University of Pennsylvania, 3400 Spruce Street, 2 Dulles, Philadelphia, PA 19104, USA
    Curr Treat Options Gastroenterol 10:464-73. 2007
  8. doi request reprint Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin
    K R Reddy
    GI Division, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Viral Hepat 15:129-36. 2008
  9. ncbi request reprint Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD)
    K Rajender Reddy
    Gastrointestinal Division, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Semin Liver Dis 24:33-8. 2004
  10. doi request reprint Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients
    K R Reddy
    Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    J Viral Hepat 16:724-31. 2009

Research Grants

Detail Information

Publications101 found, 100 shown here

  1. ncbi request reprint Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C
    K Rajender Reddy
    Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Adv Drug Deliv Rev 54:571-86. 2002
    ..Peginterferon alfa-2a (40 KD) has comparable safety to interferon alfa-2a. The addition of ribavirin to peginterferon alfa-2a (40 KD) further enhances the therapeutic benefit for patients with hepatitis C...
  2. doi request reprint Hepatitis C virus. Preface
    K Rajender Reddy
    Department of Hepatology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Clin Liver Dis 12:xiii-xiv. 2008
  3. pmc Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C
    K Rajender Reddy
    University of Pennsylvania, Philadelphia, PA, USA
    Clin Trials 9:102-12. 2012
    ..However, the safety and efficacy of silymarin have not been studied systematically in chronic hepatitis C...
  4. doi request reprint Response-guided and -unguided treatment of chronic hepatitis C
    K Rajender Reddy
    Department of Medicine, Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia 19104, USA
    Liver Int 32:64-73. 2012
    ..The proper identification of those who might benefit from extended duration HCV therapy will undoubtedly lead to optimal care and outcomes...
  5. ncbi request reprint Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment
    K Rajender Reddy
    University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Clin Gastroenterol Hepatol 5:124-9. 2007
    ..We evaluated the effects of ribavirin and peginterferon alfa-2a dose reductions on SVR in patients infected with HCV genotype 1...
  6. doi request reprint Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads
    K Rajender Reddy
    Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Gastroenterology 139:1972-83. 2010
    ..We evaluated intensified therapy with peginterferon alfa-2a plus ribavirin...
  7. ncbi request reprint Coagulopathy in liver disease
    Wojciech Blonski
    K Rajender Reddy, MD Division of Gastroenterology, Hospital of the University of Pennsylvania, 3400 Spruce Street, 2 Dulles, Philadelphia, PA 19104, USA
    Curr Treat Options Gastroenterol 10:464-73. 2007
    ..Liver transplantation completely restores impaired coagulation abnormalities and is the ultimate intervention that corrects coagulopathy of advanced liver disease and liver failure...
  8. doi request reprint Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin
    K R Reddy
    GI Division, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Viral Hepat 15:129-36. 2008
    ..Steatosis is significantly more common in genotype 3 compared with other genotypes, and in these patients, an SVR is associated with steatosis clearance...
  9. ncbi request reprint Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD)
    K Rajender Reddy
    Gastrointestinal Division, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Semin Liver Dis 24:33-8. 2004
    ..The much-increased sustained virological response rates observed with pegylated IFN alfa-2a (40 kD) and pegylated IFN alfa-2b (12 kD) support the rationale for pegylation of IFN...
  10. doi request reprint Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients
    K R Reddy
    Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    J Viral Hepat 16:724-31. 2009
    ..More frequent dose modifications of ribavirin in those >50 years likely contributed to the observed higher relapse rates...
  11. doi request reprint Ribavirin: current role in the optimal clinical management of chronic hepatitis C
    K Rajender Reddy
    GI Division, University of Pennsylvania, 2 Dulles, 3400 Spruce Street, Philadelphia, PA 19104, USA
    J Hepatol 50:402-11. 2009
    ..Despite these recent advances in our knowledge, many questions remain, such as whether the role of ribavirin will change or even be eliminated as new therapies are developed...
  12. doi request reprint Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein
    Stephen A Harrison
    Division of Gastroenterology and Hepatology, Brooke Army Medical Center, Fort Sam Houston, San Antonio, TX 78234, USA
    J Clin Gastroenterol 47:271-9. 2013
    ..Our aim was to determine whether SVR rates in patients with low/elevated LDL can be improved by dose intensification...
  13. doi request reprint Transplantation: impact of pretransplant renal insufficiency
    Ranjeeta Bahirwani
    Division of Hepatology, University of Pennsylvania Health System, Philadelphia, PA 19010, USA
    Liver Transpl 14:665-71. 2008
    ..In conclusion, few patients with preexisting renal dysfunction, especially if <12 weeks duration, experience a significant drop in eGFR post-OLTa...
  14. doi request reprint Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed Database
    Vincent Lo Re
    Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Pharmacoepidemiol Drug Saf 22:861-72. 2013
    ....
  15. ncbi request reprint Effects of hepatitis C-induced liver fibrosis on survival in kidney transplant candidates
    Mical S Campbell
    Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Dig Dis Sci 52:2501-7. 2007
    ..Kidney transplantation alone may be considered in patients with hepatitis C with compensated cirrhosis or bridging fibrosis...
  16. pmc Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial
    Michael W Fried
    UNC Liver Center, Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, NC 27599, USA
    JAMA 308:274-82. 2012
    ..The botanical product silymarin, an extract of milk thistle, is commonly used by patients to treat chronic liver disease, despite scant and conflicting evidence of its efficacy...
  17. pmc Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation
    Norah A Terrault
    Department of Medicine, Division of Gastroenterology, University of California at San Francisco, San Francisco, CA, USA
    Liver Transpl 13:122-9. 2007
    ..Important predictors of graft loss in HCV-infected patients were limited LDLT experience, pretransplant HCC, and higher MELD at transplantation...
  18. ncbi request reprint T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C
    David E Kaplan
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia 19104, USA
    Hepatology 41:1365-75. 2005
    ..The association between treatment outcome and phytohemagglutinin response suggests more global and antigen-nonspecific mechanisms for therapeutic HCV clearance...
  19. ncbi request reprint Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease
    Rolland C Dickson
    Division of Gastroenterology and Hepatology, Mayo Clinic Foundation, Jacksonville, FL 32216, USA
    Liver Transpl 12:124-33. 2006
    ..In conclusion, this study provides a rationale for the use of lower HBIg doses in HBV patients with suppressed replication undergoing LT...
  20. ncbi request reprint Racial difference in mortality among U.S. veterans with HCV/HIV coinfection
    Nathan A Merriman
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Am J Gastroenterol 101:760-7. 2006
    ..This study was performed to examine the impact of viral coinfections and race on clinical and virological outcome of hepatitis C virus (HCV) infection...
  21. ncbi request reprint Recurrence of diseases following orthotopic liver transplantation
    David S Kotlyar
    University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Am J Gastroenterol 101:1370-8. 2006
    ..Expert clinical management may help prevent and treat complications associated with disease recurrence...
  22. pmc Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era
    David Goldberg
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Liver Transpl 17:1355-63. 2011
    ....
  23. ncbi request reprint Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era
    Paige M Porrett
    The University of Pennsylvania Department of Surgery, Philadelphia, PA 19103, USA
    Liver Transpl 12:665-73. 2006
    ..25%) (P > 0.1). In conclusion, viable tumor frequently persists after pre-transplant locoregional therapy, and neoadjuvant treatment does not appear to improve post-transplant outcomes in the current MELD era...
  24. pmc Underreporting of liver transplant waitlist removals due to death or clinical deterioration: results at four major centers
    David Goldberg
    Department of Medicine, Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Transplantation 96:211-6. 2013
    ..Of particular importance for transplant policy and practice is whether patients' outcomes are coded properly...
  25. ncbi request reprint Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation
    Mical S Campbell
    Division of Gastroenterology, University of Pennsylvania Health System, Philadelphia, PA 19104, USA
    Liver Transpl 11:1048-55. 2005
    ..01) after transplantation. In conclusion, duration, but not cause, of renal dysfunction predicts renal outcome in OLTa recipients. Prospective studies may use duration of renal dysfunction to help identify CKLT candidates...
  26. ncbi request reprint Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C
    David E Kaplan
    Gastroenterology Division, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    Gastroenterology 132:654-66. 2007
    ..Although HCV-specific CD4 T-cell response is associated with HCV clearance, less is known about virus-specific CD8 T-cell or neutralizing antibody (nAb) responses and the role of CD4 help in their induction during acute infection...
  27. ncbi request reprint Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapy
    Vincent Lo Re
    Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, 423 Guardian Drive, Philadelphia, PA 19104, USA
    J Acquir Immune Defic Syndr 44:344-50. 2007
    ..Clinical observations suggest that patients with HIV/hepatitis C virus (HCV) may lose body weight during dual therapy, but this has not been confirmed analytically...
  28. pmc Histologic predictors of fibrosis progression in liver allografts in patients with hepatitis C virus infection
    Zina Meriden
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Clin Gastroenterol Hepatol 8:289-96, 296.e1-8. 2010
    ..Recurrent hepatitis C with ensuing fibrosis is the leading cause of liver allograft loss. We investigated whether histologic features in early posttransplant liver biopsies could predict the rate of fibrosis progression in this population...
  29. doi request reprint Chronic kidney disease after orthotopic liver transplantation: impact of hepatitis C infection
    Ranjeeta Bahirwani
    Division of Gastroenterology and Hepatology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Transplantation 91:1245-9. 2011
    ..Hepatitis C virus (HCV) infection has been shown to be a potential risk factor for the development of chronic kidney disease in liver transplant recipients...
  30. ncbi request reprint Association between model for end-stage liver disease and spontaneous bacterial peritonitis
    Keith L Obstein
    Department of Medicine, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Am J Gastroenterol 102:2732-6. 2007
    ..To determine whether a greater Model for End-Stage Liver Disease (MELD) score is associated with a greater risk of spontaneous bacterial peritonitis (SBP)...
  31. pmc Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis
    David S Goldberg
    Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce Street, 9 Penn Tower, Philadelphia, PA 19104, USA
    Liver Transpl 19:250-8. 2013
    ..The data call into question the systematic granting of exception points or referral for living donor transplantation due to a perceived risk of increased waitlist mortality...
  32. pmc Cost of preventing variceal rebleeding with transjugular intrahepatic portal systemic shunt and distal splenorenal shunt
    Thomas D Boyer
    Department of Medicine, University of Arizona, Liver Research Institute, Tucson, AZ 85724, USA
    J Hepatol 48:407-14. 2008
    ..We examined the cost and cost effectiveness of distal splenorenal shunt (DSRS) and transjugular intrahepatic portosystemic shunt (TIPS) in the prevention of variceal rebleeding...
  33. doi request reprint Outcomes after liver transplantation: chronic kidney disease
    Ranjeeta Bahirwani
    University of Pennsylvania, Philadelphia, PA, USA
    Liver Transpl 15:S70-4. 2009
    ..It is important to identify pre-liver transplant patients at high risk for early evolution of chronic kidney disease post-transplant in order to appropriately select patients for combined liver/kidney transplantation...
  34. ncbi request reprint Hepatitis C virus infection and immunomodulatory therapies
    Kimberly A Forde
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Clin Liver Dis 13:391-401. 2009
    ..In this article, the authors discuss immunomodulatory therapies and clinical trials in the treatment of HCV infection...
  35. ncbi request reprint Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma
    Stephen N Wong
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Liver Transpl 13:334-42. 2007
    ..In conclusion, despite more advanced liver disease and a lower rate of transplantation, ITT survival of patients listed for HBV-cirrhosis was comparable to those with HBV-HCC, possibly related to beneficial effects of antiviral therapy...
  36. pmc Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study
    Vincent Lo Re
    Philadelphia VA Medical Center, Philadelphia, PA, USA Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Pharmacoepidemiol Drug Saf 20:689-99. 2011
    ..We determined the ability of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events within the Veterans Aging Cohort Study (VACS)...
  37. pmc Current trends in living donor liver transplantation for primary sclerosing cholangitis
    David Seth Goldberg
    Department of Medicine, Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA, USA
    Transplantation 91:1148-52. 2011
    ..To overcome such barriers in the post-MELD era, clinicians might refer patients with PSC, relative to patients without PSC, for living donor transplants more frequently...
  38. pmc Factors that predict short-term intensive care unit mortality in patients with cirrhosis
    Ranjeeta Bahirwani
    Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Clin Gastroenterol Hepatol 11:1194-1200.e2. 2013
    ..We aimed to identify factors that predict early (7 d) mortality among patients with cirrhosis admitted to the intensive care unit (ICU) and to develop a risk-stratification model...
  39. ncbi request reprint Hepatitis C with normal liver enzymes: to treat or not to treat. Con: most patients should not be treated
    K Rajender Reddy
    University of Pennsylvania, USA
    Am J Gastroenterol 99:973-5. 2004
  40. doi request reprint Pruritus in chronic cholestatic liver disease
    Chalermrat Bunchorntavakul
    Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania, Philadelphia, USA
    Clin Liver Dis 16:331-46. 2012
    ..Experimental interventions, and the management of pruritus in certain conditions such as intrahepatic cholestasis of pregnancy and benign recurrent intrahepatic cholestasis, are also briefly reviewed...
  41. ncbi request reprint Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population
    Barbara A Piasecki
    University of Pennsylvania School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Hepatology 40:892-9. 2004
    ..016), while HBV coinfection was positively associated with HCV clearance (unadjusted OR 5.0; 95% CI, 1.26-28.6; P =.008). In conclusion, the likelihood of spontaneous clearance of HCV may be influenced by alcohol and viral coinfections...
  42. ncbi request reprint The importance of clinical parameters when differentiating cholestatic hepatitis C virus from allograft rejection
    G W Neff
    Department of Medicine, University of Cincinnati, Cincinnati, Ohio 45267 0595, USA
    Transplant Proc 37:4397-402. 2005
    ..Our objective was to determine the diagnostic accuracy of clinical and histological parameters in liver transplant recipients with RHCV and concurrent cholestasis...
  43. doi request reprint Acute-on-chronic liver failure before liver transplantation: impact on posttransplant outcomes
    Ranjeeta Bahirwani
    Division of Gastroenterology and Hepatology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Transplantation 92:952-7. 2011
    ..It is unclear whether patients who develop acute-on-chronic liver failure (ACLF) have poor outcomes after liver transplantation...
  44. pmc Racial and ethnic differences in presentation, etiology, and outcomes of acute liver failure in the United States
    Kimberly A Forde
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania, 3400 Spruce Street, 3 Ravdin, Philadelphia, Pennsylvania 19104, USA
    Clin Gastroenterol Hepatol 7:1121-6. 2009
    ..In patients with chronic liver disease, race plays a role in the rate of survival after transplantation. It is not known how race and ethnicity influence the presentation, etiology, and outcomes in patients with acute liver failure (ALF)...
  45. ncbi request reprint Rising incidence of hepatocellular carcinoma: the role of hepatitis B and C; the impact on transplantation and outcomes
    David E Kaplan
    Division of Gastroenterology and Hepatology, University of Pennsylvania School of Medicine, 3 Raydin, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Clin Liver Dis 7:683-714. 2003
    ..LDLT may remain an option for high-risk patients affording tumor-free survival for some otherwise terminal patients...
  46. pmc Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience
    Jasmohan S Bajaj
    Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA 23249, USA
    Hepatology 56:2328-35. 2012
    ..The model for mortality included admission MELD (odds ratio [OR]: 1.12), heart rate (OR: 1.03) albumin (OR: 0.5), and second infection (OR: 4.42) as significant variables...
  47. ncbi request reprint Reconstitution of hepatitis C virus-specific T-cellmediated immunity after liver transplantation
    Scott J Weston
    Department of Medicine, Oregon Health and Science University, USA
    Hepatology 41:72-81. 2005
    ..Supplementary material for this article can be found on the HEPATOLOGY website (http://interscience. wiley.com/jpages/0270-9139/suppmat/index.html)...
  48. ncbi request reprint Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome
    Kirti Shetty
    Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Liver Transpl 10:911-8. 2004
    ..e., vascular invasion and multifocality. Present UNOS selection criteria for HCC based on tumor burden appear to provide adequate discriminatory power in predicting outcome of OLT...
  49. doi request reprint Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series
    Calvin Q Pan
    Division of Liver Diseases, Department of Medicine, Mount Sinai Medical Center, Mount Sinai School of Medicine, New York, NY, USA
    Dig Dis Sci 57:2423-9. 2012
    ..Use of TDF to prevent vertical transmission (VT) by such mothers has not been evaluated...
  50. ncbi request reprint Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list
    Roy D Bloom
    Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Am J Transplant 5:139-44. 2005
    ..Diabetic HCV+ kidney candidates are therefore a patient subgroup that requires frequent and careful reevaluation to ensure ongoing transplantability...
  51. ncbi request reprint Factors that influence the severity of recurrent hepatitis C virus following liver transplantation
    Steven B Porter
    Department of Medicine, GI Division, Hospital of the University of Pennsylvania, 3400 Spruce Street, 3 Ravdin, Philadelphia, PA 19104, USA
    Clin Liver Dis 7:603-14. 2003
    ..Finally, features that may influence outcomes over which there is no control include: recipient age, recipient gender, and donor age (in the case of cadaveric donors). Unfortunately, the best-case scenario is uncommon...
  52. doi request reprint Biologic and clinical features of benign solid and cystic lesions of the liver
    Oren Shaked
    Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Gastroenterol Hepatol 9:547-62.e1-4. 2011
    ..These advances have led to constant adjustments in management approaches to benign hepatic lesions. We review the biologic and clinical features of some common hepatic lesions, to guide diagnosis and management strategies...
  53. doi request reprint Hepatitis C virus infection and hepatocellular carcinoma
    Wojciech Blonski
    Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Clin Liver Dis 12:661-74, x. 2008
    ..Although several studies suggested the preventive effect of interferon from developing HCC in HCV-infected individuals, these findings need to be validated in large prospective and randomized trials...
  54. doi request reprint End-stage renal disease after liver transplantation in patients with pre-transplant chronic kidney disease
    Ranjeeta Bahirwani
    Division of Gastroenterology and Hepatology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
    Clin Transplant 28:205-10. 2014
    ..Renal dysfunction prior to liver transplantation has a marked impact on post-transplant kidney outcomes...
  55. ncbi request reprint Allograft survival following adult-to-adult living donor liver transplantation
    Peter L Abt
    Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
    Am J Transplant 4:1302-7. 2004
    ..Analysis of this early experience with AALDLT suggests that allograft failure may be higher than among recipients of a cadaveric liver...
  56. doi request reprint Alcohol consumption by cirrhotic subjects: patterns of use and effects on liver function
    Michael R Lucey
    Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792 5124, USA
    Am J Gastroenterol 103:1698-706. 2008
    ....
  57. ncbi request reprint Postoperative jaundice
    Thomas W Faust
    Division of Gastroenterology, Department of Internal Medicine, The University of Pennsylvania School of Medicine, 3 Ravdin, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Clin Liver Dis 8:151-66. 2004
    ..Treatment includes removal of offending drugs, supportive care, broad-spectrum antibiotic agents with drainage of infected fluid collections, adjustment of TPN, and either cholecystectomy or cholecystostomy, respectively...
  58. pmc Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis
    David E Kaplan
    Research Section, Philadelphia VA Medical Center, Research A216, 3900 Woodland Avenue, Philadelphia, PA 19104, USA
    J Hepatol 48:903-13. 2008
    ..In this study, we examined the role of HCV-specific T-cell IL-10 response in patients with acute and chronic HCV infection...
  59. doi request reprint NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection
    D Alan Herbst
    University of Pennsylvania, Department of Gastroenterology Research, Philadelphia, PA 19104, USA
    Expert Opin Investig Drugs 22:1337-46. 2013
    ..The treatment landscape is rapidly evolving as a number of direct-acting antivirals (DAA) are being developed in clinical trials...
  60. ncbi request reprint Association between proton pump inhibitor use and spontaneous bacterial peritonitis
    Mical S Campbell
    Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Dig Dis Sci 53:394-8. 2008
    ..22 (95% confidence interval: 0.52-2.87) and 1.05 (0.43-2.57), respectively. In conclusion, we did not find a positive association between PPI use and spontaneous bacterial peritonitis...
  61. ncbi request reprint Evaluation of nonmalignant liver masses
    Wojciech Blonski
    Department of Medicine, Division of Gastroenterology, 3 Ravdin Building, Hospital of the University of Pennsylvania, Philadelphia, PA 19014, USA
    Curr Gastroenterol Rep 8:38-45. 2006
    ..An invasive approach is seldom required. This review discusses the various characteristics of the most common benign liver lesions and recommends a practical approach...
  62. ncbi request reprint Liver transplantation for metastatic neuroendocrine tumor: a case report and review of the literature
    Wojciech C Blonski
    Gastroenterology Division, University of Pennsylvania Health System, 3400 Spruce Street, 3 Ravdin Building, Philadelphia, PA 19104, USA
    World J Gastroenterol 11:7676-83. 2005
    ..We report a case of liver transplantation for metastatic neuroendocrine tumor of unknown primary source and provide a detailed review of the world literature on this controversial topic...
  63. doi request reprint Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies
    Vincent Lo Re
    Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104 6021, USA
    Pharmacoepidemiol Drug Saf 21:1202-15. 2012
    ..To describe the design and rationale of a series of postmarketing studies to examine the safety of saxagliptin, an oral dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus, in real-world settings...
  64. ncbi request reprint Noncirrhotic portal hypertension: another cause of liver disease in HIV patients
    Manuel Mendizabal
    Department of Gastroenterology, University of Pennsylvania, Philadelphia, USA
    Ann Hepatol 8:390-5. 2009
    ..Prolonged exposure to ART, specially ddl, can play a pathogenic role. Rarely, liver synthetic function is sufficiently severe to warrant liver transplantation...
  65. doi request reprint Approach to a liver mass
    Oren Shaked
    School of Medicine, 2 Dulles, 3400 Spruce Street, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Clin Liver Dis 13:193-210. 2009
    ..Various imaging modalities can be utilized to accurately diagnose such masses without resort to more invasive diagnostic measures...
  66. ncbi request reprint Portal flow and arterioportal shunting after transjugular intrahepatic portosystemic shunt creation
    Maxim Itkin
    Section of Interventional Radiology, Department of Radiology, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Vasc Interv Radiol 17:55-62. 2006
    ..This study sought to quantify this shunting in patients undergoing TIPS creation and/or revision with use of a direct catheter-based technique and by measuring changes in blood oxygenation within the TIPS and the PV...
  67. ncbi request reprint Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy
    Mical S Campbell
    Division of Gastroenterology, University of Pennsylvania Health Services, Philadelphia, PA 19104, USA
    Hepatology 42:635-40. 2005
    ..Competing effects of hepatic encephalopathy, requirement for repeated LVP, and need for hospitalizations explain similar changes in quality of life between the two groups...
  68. doi request reprint Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection
    David Alan Herbst
    University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Expert Opin Investig Drugs 22:527-36. 2013
    ..Despite this, effective therapies for chronic HCV for all genotypes represent a largely unmet need...
  69. doi request reprint Immune dysfunction and infections in patients with cirrhosis
    Alexander R Bonnel
    Division of Gastroenterology Hepatology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Clin Gastroenterol Hepatol 9:727-38. 2011
    ..We review the pathogenesis of infections in these patients, along with diagnostic and management strategies...
  70. ncbi request reprint Endoscopic management of biliary complications after adult living donor liver transplantation
    Janak N Shah
    Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia 19104, USA
    Am J Gastroenterol 99:1291-5. 2004
    ..We assessed the role of endoscopic retrograde cholangiopancreatography (ERCP) in the diagnosis and management of biliary complications following LDLT...
  71. ncbi request reprint One two tandem of lamivudine and inferferon might work for patients with chronic hepatitis B who failed inferferon monotherapy
    David D Kaplan
    University of Pennsylvania, Philadelphia, USA
    Am J Gastroenterol 97:2465-7. 2002
  72. ncbi request reprint Management of hepatitis C virus in special populations: patient and treatment considerations
    Robert G Gish
    Liver Transplant Program and Division of Hepatology and Complex GI, California Pacific Medical Center, 2340 Clay Street 232, San Francisco, CA 94115, USA
    Clin Gastroenterol Hepatol 3:311-8. 2005
    ..Close monitoring and management of therapeutic side effects are required to assist these patients in adhering to therapy...
  73. ncbi request reprint Hepatitis C virus-infected donors in liver transplantation
    Richard Peek
    Gastroenterology 133:381-2. 2007
  74. ncbi request reprint Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis
    Richard K Sterling
    Virginia Commonwealth University Health Systems, Richmond, Virginia, USA
    Am J Gastroenterol 102:2196-205. 2007
    ..The aim of this prospective study was to compare the clinical utility of AFP-L3% with that of total AFP in North American patients...
  75. ncbi request reprint Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin
    Maria H Sjogren
    Walter Reed Army Medical Center, Washington, DC 20307, USA
    Dig Dis Sci 52:1540-7. 2007
    ..It is possible that if consensus interferon is administered daily rather than three times weekly, eradication of HCV could be achieved in a larger proportion of patients infected with HCV genotype 1...
  76. ncbi request reprint Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy
    John G McHutchison
    Duke Clinical Research Institute, Division of Gastroenterology Duke University, Durham, North Carolina 27705, USA
    Am J Gastroenterol 102:880-9. 2007
    ..In the meantime, physicians must make the best possible use of the available options for managing anemia, especially in select patient groups who are most at risk for anemia and its complications...
  77. ncbi request reprint Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy
    Shengyuan Luo
    University of Maryland School of Medicine, USA
    Clin Gastroenterol Hepatol 3:499-506. 2005
    ..We hypothesized that racial differences in IFN-stimulated antiviral gene induction during treatment might be responsible...
  78. ncbi request reprint Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
    ..We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C...
  79. ncbi request reprint Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis
    Paul J Pockros
    Division of Gastroenterology Hepatology, Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 45:569-78. 2007
    ..IFN-gamma1b was well tolerated. There were similar numbers of deaths in all 3 arms (5, 5, and 4, respectively), and most were related to complications of cirrhosis...
  80. ncbi request reprint First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline
    Jennifer E Layden
    University of Illinois at Chicago, Chicago, IL, USA
    J Viral Hepat 9:340-5. 2002
    ..This might be explained by a viral dynamics model assuming a jump-start of the immune response when viral loads are reduced below a threshold, subsequently giving rise to a faster 2nd phase decline slope...
  81. ncbi request reprint Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C
    Thomas J Layden
    University of Illinois at Chicago, Chicago, IL
    J Viral Hepat 9:334-9. 2002
    ..They also suggest that early viral kinetics during the first month of therapy can predict non-SVR and thus save a patient a year long treatment which is fraught with side-effects and significant cost...
  82. ncbi request reprint Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)
    Samuel S Lee
    Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1
    J Hepatol 37:500-6. 2002
    ..We evaluated the prognostic value of baseline factors and early viral RNA among patients treated with peginterferon alfa-2a (40KD)...
  83. ncbi request reprint Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy
    Donald M Jensen
    Center for Liver Diseasees, University of Chicago Hospitals, 60637, USA
    Hepatology 43:954-60. 2006
    ..In conclusion, patients infected with HCV genotype 1 and treated with peginterferon alpha-2a/ribavirin sustained a RVR 24% of the time. This portends an 89% probability of a SVR after 24 weeks of treatment...
  84. ncbi request reprint Pegylated interferons
    Umaprasanna S Karnam
    Department of Gastroenterology and Hepatology, Central Utah Medical Clinic, 36 North 1100 East, American Fork, UT 84003, USA
    Clin Liver Dis 7:139-48. 2003
    ..Pegylated IFNs with ribavirin are the standard of care for treating patients with chronic HCV who have not been treated previously...
  85. ncbi request reprint Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practice
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Health System Medical College of Virginia, Richmond, Virginia 23298, USA
    Am J Gastroenterol 98:1159-66. 2003
    ..The present study was performed to evaluate the impact of the international unit standard for measuring HCV RNA in the management of patients with chronic hepatitis C virus (HCV) infection...
  86. ncbi request reprint Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial
    Paul J Pockros
    Division of Gastroenterology Hepatology, Scripps Clinic, La Jolla, California 92037, USA
    Am J Gastroenterol 99:1298-305. 2004
    ..This study compared the efficacy and safety of peginterferon alpha-2a 135 microg/wk, peginterferon alpha-2a 180 microg/wk and interferon alpha-2a in patients with chronic hepatitis C...
  87. doi request reprint Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C
    Kirti Shetty
    Division of Transplantation, Georgetown University Hospital, Washington, DC 20007, USA
    Liver Transpl 14:534-40. 2008
    ..Occult HBV infection is strongly associated with the presence of anti-HBc, history of injection drug use, and explant-proven HCC...
  88. doi request reprint Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a
    Patrick Marcellin
    Service d hépatologie and INSERM CRB3, University of Paris, Hopital Beaujon, Clichy, France
    Liver Int 28:477-85. 2008
    ..Pooled data from five studies of peginterferon alpha-2a in patients with chronic HCV infection (CHC) were compared with two studies of the drug in patients with chronic HBV infection (CHB)...
  89. ncbi request reprint Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1
    Lennox J Jeffers
    Miami Veterans Affairs Medical Center, Miami, FL, USA
    Hepatology 39:1702-8. 2004
    ....
  90. ncbi request reprint Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
    Peter Ferenci
    Medical University of Vienna, Vienna, Austria
    J Hepatol 43:425-33. 2005
    ..Prediction of sustained virological response (SVR) during treatment would allow clinicians to identify patients most likely to benefit from therapy...
  91. ncbi request reprint Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels
    Stefan Zeuzem
    Saarland University Hospital, Homburg Saar, Germany
    Gastroenterology 127:1724-32. 2004
    ....
  92. ncbi request reprint Competing risks analysis of predictors of delisting owing to tumor progression in liver transplant candidates with hepatocellular carcinoma
    Noriyo Yamashiki
    Division of Transplantation, Department of Surgery, University of Miami School of Medicine, Miami, FL, USA
    Am J Transplant 4:774-81. 2004
    ..001). In conclusion, the initial AFP level may be useful along with tumor stage in defining an urgency score for liver transplant candidates with HCC...
  93. ncbi request reprint Ribavirin considerations in treatment optimization
    Geoffrey Dusheiko
    Royal Free Hospital, London, United Kingdom
    Antivir Ther 13:23-30. 2008
    ..Here, we discuss how optimizing the ribavirin component of combined therapy for HCV is an essential part of treatment optimization...
  94. doi request reprint Rapid virologic response: a new milestone in the management of chronic hepatitis C
    Fred Poordad
    Hepatology and Liver Transplantation, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Clin Infect Dis 46:78-84. 2008
    ..This assessment is being used to individualize treatment duration, which is currently recommended as 48 weeks in patients infected with HCV genotype 1 (G1) and 24 weeks in those infected with HCV G2 or G3...
  95. doi request reprint First, do no harm: The question of liver biopsy in living liver donors
    Kim M Olthoff
    Liver Transpl 14:420-2. 2008
  96. ncbi request reprint Laparoscopic observations of the liver in hereditary hemorrhagic telangiectasia
    Wojciech Blonski
    Scand J Gastroenterol 42:1512-3. 2007
  97. ncbi request reprint Doctor Griffin Rodgers at helm of the National Institute of Diabetes and Digestive and Kidney Diseases
    Richard Peek
    Gastroenterology 133:380-1. 2007
  98. ncbi request reprint Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection
    Arie Regev
    Division of Hepatology, Center for Liver Diseases, University of Miami School of Medicine, Florida 33136, USA
    Am J Gastroenterol 97:2614-8. 2002
    ....
  99. doi request reprint Diagnosis and treatment of hepatocellular carcinoma
    Hashem B El-Serag
    Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas 77030, USA
    Gastroenterology 134:1752-63. 2008
    ..In this article, we present a summary of the most recent information on screening, diagnosis, staging, and different treatment modalities of HCC, as well as our recommended management approach...
  100. ncbi request reprint The North American Study for the Treatment of Refractory Ascites
    Arun J Sanyal
    Department of Internal Medicine, Virginia Commonwealth University Health System, Richmond, Virginia, USA
    Gastroenterology 124:634-41. 2003
    ..The clinical utility of transjugular intrahepatic portosystemic shunts (TIPS) vis-à-vis total paracentesis in the management of refractory ascites is unclear...
  101. ncbi request reprint Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine
    Jose R Nery
    University of Miami School of Medicine, Department of Surgery, Division of Liver GI Transplantation, Miami, FL, USA
    Transplantation 75:1179-86. 2003
    ..We reviewed our experience with liver grafts from hepatitis-B surface antigen (HBsAg)(-), antibody to core antigen (anti-HBc)(+) donors...

Research Grants1

  1. A phase I/II trial of silymarin for chronic liver diseases
    Rajender Reddy; Fiscal Year: 2007
    ..This study will examine the safety and tolerability of various doses of milk thistle as well as start to explore its role in hepatitis C. ..